Macitentan

OPSUMIT

Endothelin Receptor Antagonist

NADAC/unit N/A

No Shortage Tier 1: 15.2% PA Req: 76.6% 5 Manufacturers 5 ANDAs

OPSUMIT is an endothelin receptor antagonist (ERA) indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) in adults to reduce the risks of disease progression and hospita....

Covered Lives

Generic Manufacturers

ACTELION PHARMACEUTICALS US INCALEMBIC PHARMACEUTICALS LTDAUROBINDO PHARMA LTDLAURUS LABS LTDMSN LABORATORIES PRIVATE LTDSUN PHARMACEUTICAL INDUSTRIES LTD

Explore in the Ecosystem

rxsaver.aiCompare prices for Macitentan drfinder.aiFind doctors who prescribe Macitentan rxbenefits.aiEmployer cost impact analysis clinicalrx.aiClinical profile: Macitentan

Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.